Would you recommend this? (No I wanted) If not, what would you recommend? (Chantix is the medication of choice)    Include medication pharmacotherapeutics, pharmacodynamics, pharmacokinetics, patient monitoring, and education

Would you recommend this? (No I wanted) If not, what would you recommend? (Chantix is the medication of choice)    Include medication pharmacotherapeutics, pharmacodynamics, pharmacokinetics, patient monitoring, and education

27-year-old Latino male presents to your office to inquire about quitting smoking. He has tried NicoDerm in the past with no success. He states that a few of his friends are “vaping” and wonders if this would be a good option for him. Discuss why vaping is not good.

Instructions

Would you recommend this? (No I wanted) If not, what would you recommend? (Chantix is the medication of choice)    Include medication pharmacotherapeutics, pharmacodynamics, pharmacokinetics, patient monitoring, and education.

 

Use these Articles for References

https://www.pfizermedicalinformation.com/en-us/chantix?tab=mg (This is a website to chanti)

 

https://www.sciencemag.org/news/2019/11/how-safe-vaping-new-human-studies-assess-chronic-harm-heart-and-lungs (Vaping article)

 

 

This is an example of a student’s discussion of smoking. This can be used as an example.

A 27-year-old Latino male presents to your office to inquire about quitting smoking. He has tried NicoDerm in the past with no success. He states that a few of his friends are “vaping” and wonders if this would be a good option for him.

  1. Would you recommend this?
  • No, I would not recommend vaping. According to O’Neill (2019), there have been six deaths related to vaping in the United States. O’Neill (2019), stated that vaping can cause severe lung damage.
  1. If not, what would you recommend?
  • I would prescribe Bupropion SR (Zyban).
  1. Include medication pharmacotherapeutics, pharmacodynamics, pharmacokinetics, patient monitoring, and education.
  • Bupropion SR pharmacotherapeutics mechanism of action regarding smoking cessation is unknown. According to Katzung et al. (2012), the drug may imitate the effects nicotine has on dopamine and norepinephrine. Nicotine receptors may be antagonized by the drug and relapse might be prevented by diminishing the reinforcing properties of nicotine (Katzung, Masters, & Trevor, 2012).
  • Bupropion SR pharmacodynamics actions are poorly understood. Animal studies have shown that the drug’s major metabolite hydroxybupropion is an inhibitor of norepinephrine and dopamine reuptake; which enhances both noradrenergic and dopaminergic neurotransmission (Katzung, Masters, & Trevor, 2012). Animal studies have shown that the drug substantially increases the presynaptic release of norepinephrine and dopamine, as well (Katzung, Masters, & Trevor, 2012).
  • Pharmacokinetics: Bupropion half-life is eight to ten hours. The drug is transformed into three active metabolites hydroxybupropion, threohydrobupropion, and erythrohydrobupropion (Guzman, n.d.).  The metabolites half-lives are 24 hours or more (Guzman, n.d.). The drug is absorbed rapidly with 85% of mean protein binding (Katzung, Masters, & Trevor, 2012).
  • Patient education would include:
  • Inform the patient to take the two doses eight hours apart.
  • Educate the patient on the side effects of the drug such as dry mouth, insomnia, or seizures.
  • Inform the patient to avoid taking the drug around bedtime to avoid insomnia.
  • Inform the patient that he/she can continue to smoke for a week after starting the medicine because it takes at least a week for the drug to be therapeutic.
  • Inform the patient to set a quit date during week two of therapy.
  • Encourage the patient to participate in a behavioral therapy program during and after drug therapy.
  • Inform the patient not to take Wellbutrin, Wellbutrin SR, or Wellbutrin XL while taking Zyban because these medications all contain bupropion.
  • Inform the patient that monoamine oxidase inhibitors should not be used during or within 14 days of bupropion SR treatment; it can increase bupropion toxicity.
  • Inform the patient that Zyban SR should not be chewed or crushed; damage to the sustained release formulation can occur, which can increase the risk of overdose and adverse events.
  • Inform the patient that drug tapering is not required when discontinuing the drug (Arcangelo, Peterson, Wilbur, & Reinhold, 2017).
  • Patient monitoring:
  • If no significant improvements are seen by week seven of the drug therapy, the treatment is most likely unsuccessful, and the medication should be discontinued.
  • If a patient successfully quits after seven to 12 weeks of the drug therapy the patient should be considered for continuation of bupropion SR therapy (Arcangelo, Peterson, Wilbur, & Reinhold, 2017).

 

References